1276 Stock Overview

A pharmaceutical company, researches, develops, manufactures, and commercializes drugs in China and internationally. More details

1276 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	3/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 15.5% below our estimate of its fair value

Earnings are forecast to grow 12.34% per year

Earnings grew by 54.4% over the past year

Risk Analysis

Shares are highly illiquid

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Jiangsu Hengrui Medicine Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Jiangsu Hengrui Medicine
Historical stock prices
Current Share Price	CN¥55.15
52 Week High	CN¥60.50
52 Week Low	CN¥55.15
Beta	0.44
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	1276	HK Pharmaceuticals	HK Market
7D	n/a	8.7%	1.8%
1Y	n/a	26.1%	16.9%

Return vs Industry: Insufficient data to determine how 1276 performed against the Hong Kong Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 1276 performed against the Hong Kong Market.

Price Volatility

Is 1276's price volatile compared to industry and market?
1276 volatility
1276 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	7.6%
Market Average Movement	7.9%
10% most volatile stocks in HK Market	15.2%
10% least volatile stocks in HK Market	4.2%

Stable Share Price: 1276's share price has been volatile over the past 3 months compared to the Hong Kong market.

Volatility Over Time: Insufficient data to determine 1276's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1970	20,238	Ji Feng	www.hengrui.com

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes drugs in China and internationally. The company develops antineoplastic drugs; surgery medications; medicines for oncology, autoimmune diseases, pain management, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory system diseases, hematological diseases, neurological diseases, and ophthalmology, etc.; analgesia and anesthesia products; and contrast agents. It is also involved in technical consulting; training; investment advisory; technology development; project; information; and investing services, as well as the import and export of pharmaceutical products.

Jiangsu Hengrui Medicine Co., Ltd. Fundamentals Summary

How do Jiangsu Hengrui Medicine's earnings and revenue compare to its market cap?
1276 fundamental statistics
Market cap	HK$393.16b
Earnings (TTM)	HK$7.46b
Revenue (TTM)	HK$31.84b

52.8x

P/E Ratio

12.4x

P/S Ratio

Is 1276 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1276 income statement (TTM)
Revenue	CN¥29.19b
Cost of Revenue	CN¥4.01b
Gross Profit	CN¥25.19b
Other Expenses	CN¥18.34b
Earnings	CN¥6.84b

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	1.03
Gross Margin	86.28%
Net Profit Margin	23.44%
Debt/Equity Ratio	0%

How did 1276 perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

18%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/25 02:37
End of Day Share Price	2025/05/23 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Jiangsu Hengrui Medicine Co., Ltd. is covered by 56 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ling Zhang	BNP Paribas Securities (Asia)
Changming He	BOCI Research Ltd.
Bo Li	BofA Global Research